Article Text

Download PDFPDF
MALT lymphoma of the colon: a clinicopathological review
  1. Norris Hollie1,
  2. Saja Asakrah2
  1. 1 Pathology, Beth Israel Lahey Health, Boston, Massachusetts, USA
  2. 2 Department of Pathology and Laboratory Medicine, Emory University, Atlanta, Georgia
  1. Correspondence to Dr Saja Asakrah, Emory University, Atlanta 30322-1007, Georgia; saja.asakrah{at}emory.edu

Abstract

Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) occurs in approximately 9% of non-Hodgkin B cell lymphoma. However, it occurs only rarely within the colon. The presentation is often asymptomatic, and can have multiple endoscopic appearances, including a single or multinodular polypoid lesion. Furthermore, small biopsies can make histological evaluation challenging. The 2016 WHO classification update includes many molecular features of entities and expands the differential diagnosis of lymphoid lesions of the colon. In addition to immunohistochemistry, molecular methods may be tempting to use for small difficult cases. Furthermore, treatment approaches are varied for this entity, and not well studied. Therefore, an updated review on MALT lymphoma of the colon is needed.

  • colon
  • lymphoma
  • MALT-lymphoma

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Handling editor Runjan Chetty.

  • Contributors SA (primary haematopathologist): evaluated the histopathology of the selected imaged cases, conducted immunophenotypic workup, and helped in supervising, writing and editing the review. NH (pathologist): gathered all the clinicopathologic information and took photomicrographs. He wrote the primary draft of the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; internally peer reviewed.